Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

HUTCHMED announced an expert webcast on November 5, 2026, to discuss Phase III clinical data for savolitinib in MET-driven NSCLC. The SANOVO study showed savolitinib plus TAGRISSO® reduced disease progression/death risk by 44% overall and 55% in high MET overexpression patients. The SAFFRON global Phase III trial demonstrated a 45% reduction in progression risk and 32% reduction in death risk in EGFR-mutated lung cancer after TAGRISSO® progression.